HER2DX ERBB2 score in advanced HER2-positive gastric cancer treated with trastuzumab and chemotherapy.

ESMO Open · 2025 · PMC12451336 · PMID 40913834

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

showed a trendP = 0.054so close (0.05 < p ≤ 0.1)

When analyzed as a continuous variable, the HER2DX ERBB2 score showed a trend toward higher response rates with increasing expression (OR 1.33, 95% CI 1.01-1.82, P = 0.054).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.